| 5 0 (0%) | 05-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.85 | 1-year : | 6.83 |
| Resists | First : | 5.01 | Second : | 5.85 |
| Pivot price | 4.99  |
|||
| Supports | First : | 4.98 |
Second : | 4.96 |
| MAs | MA(5) : | 5 | MA(20) : | 4.99 |
| MA(100) : | 3.83 |
MA(250) : | 4.1 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 66.6 | D(3) : | 66.6 |
| RSI | RSI(14): 72.3 | |||
| 52-week | High : | 5.3 | Low : | 2.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TSVT ] has closed below upper band by 40.2%. Bollinger Bands are 98.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.01 - 5.04 | 5.04 - 5.06 |
| Low: | 4.93 - 4.96 | 4.96 - 4.99 |
| Close: | 4.95 - 5 | 5 - 5.05 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Thu, 05 Jun 2025
Kalkine: Nasdaq Top 100 Biopharma Companies Including 2seventy Bio by Kalkine - Kalkine Media
Tue, 13 May 2025
2seventy bio Completes Merger, Delists from Nasdaq - TipRanks
Tue, 13 May 2025
2seventy bio completes merger with Bristol-Myers Squibb - Investing.com
Wed, 07 May 2025
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Tue, 25 Mar 2025
2seventy bio Inc. (TSVT) reports earnings - qz.com
Wed, 12 Mar 2025
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 82.4 (%) |
| Shares Short | 2,590 (K) |
| Shares Short P.Month | 2,750 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | -8.5 % |
| Operating Margin | -10.8 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 84.5 % |
| Gross Profit (p.s.) | -0.25 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -62.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 5.5 |
| Price to Cash Flow | -4.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|